Pluristem Therapeutics Granted New Patent amid Positive Clinical Trial

Publishing & Media

Share Tweet

Pluristem Therapeutics Granted New Patent amid Positive Clinical Trial

Granted New Patent

Stem-Cell research company Pluristem Therapeutics Inc.’s (NASDAQ: PSTI) share value has been rising steadily on a bevy of positive news the company has been releasing ranging from successful clinical trials to being granted new patents.

The latest good news came Feb. 18 when the Israel-based company announced it has been granted a new patent by the Australian Patent Office.

According to the release, patent #2007228341 covers the method and composition of matter for three-dimensional expansion of placental or adipose (fat) stromal cells, Pluristem's key technology platform. Patent claims also include methods of treatment using placental cells for numerous diseases including graft vs. host disease, heart disease, stroke, burns, loss of tissue, loss of blood, anemia, and autoimmune disorders.

Patents with similar claims have also been granted to Pluristem in Russia and in South Africa. This marks Pluristem's third patent issued in Australia and its 28th patent issued worldwide. 

Positive Clinical Trial Results

In late January, Pluristem Therapeutics also released good news that results from its early/mid-stage clinical trial indicated its placenta-derived stem cells for the treatment of muscle injury were safe and provided evidence the cells might be effective in treating orthopedic injuries.

“Patients treated with PLX-PAD had a greater improved change of maximal voluntary muscle contraction force than the placebo group,” the statement said.

The trial was conducted at the Orthopedic Clinic of the Charite University Medical School under the auspices of the Paul-Ehrlich-Institute, Germany's health authority.

Approval to provide cells

Also in January, the company says it received approval from the Paul-Ehrlich-Institute (PEI), Germany's health authority, to supply cells from its advanced, fully automated, and proprietary 3D cell expansion manufacturing platform implemented at its new state-of-the-art GMP facility.

“Pluristem's new manufacturing facility has the capability to efficiently produce over 150,000 doses of PLX cells annually, which potentially translates into significant economic value,” the statement said.

PSTI stock closed at 4.02 cents a share on Feb. 20, up 2 cents from $ 4.00 the previous day.

Find out what could be the best investor’s move when it comes to BLIN by getting the complete report here, or by cutting and pasting the following link in your Web browser:  

Growth in Ecommerce Fuels Stock’s Volume

Bridgeline Digital, Inc. (NASDAQ:BLIN) stock volume is soaring, with 307,913 shares of the Burlington-Mass. company’s stock changing hands Feb. 20, nearly twice its three-month average volume of 169,634.

Bridgeline Digital, which offers an impressive portfolio of Web development ecommerce design services, is positioning itself to ride the tidal wave that is ecommerce.

According to the results announced for the first quarter of fiscal year 2014 released Feb. 14, Bridgeline Digital’s revenue from subscription of licenses, doubled to $1.6 million in while revenue from returning clients increased by almost 42% compared to the last quarter of 2013.

Bright Future of Ecommerce

In 2014, ecommerce sales will soar to nearly $250 billion, up from $155 billion in 2009, according to Cambridge-Mass research firm Forrester.  Last year, online retail sales were up a healthy 11 percent, compared to 2.5 percent for all retail sales.

Web-influenced sales

While Bridgeline Digital stands to benefit directly because so many companies need to improve or launch an ecommerce presence, the company is also poised to benefit from what Forrester defines as “Web-influence sales.”

Forrester contends that $917 billion worth of retail sales last year were “Web-influenced.” It also asserts that online and Web-influenced offline sales combined accounted for 42% of total retail sales and will grow to 53% in 2014, influencing $1.4 billion worth of brick-and-mortar sales. 

Bottom line: companies like Bridgeline Digital that make and sell products and services that help companies improve their online design and overall presentation will benefit greatly.

But what is of paramount importance is that Bridgeline Digital delivers its services on time and within budget. These are two of the major concerns businesses have when upgrading their online presence. According to data from Framington, Mass. Research firm International Data Corp., the rate of delivery for developing and delivering Web applications on-time, on-budget, and on-spec is very poor industry wide:

- Almost 70% of Web applications developed will never reach completion or launch.

- 50% of Web applications developed will not match the original specifications or vision.

- Web application projects can average 180% over their original budget - and take twice as long to deliver as originally planned.

BLIN stock closed at $1.16 a share on Feb. 20, up 2 cents from $ 1.14 the previous day.

Find out what could be the best investor’s move when it comes to BLIN by getting the complete report here, or by cutting and pasting the following link in your Web browser:  

$12.2-million influx

On Feb. 20,  a little more than a month after Aeterna Zentaris Inc. (NASDAQ: AEZS) closed a public offering of $13.2 million, its share price closed at $1.28, up 2  cents from its close of $1.26 the previous day.

On Jan. 14, the Canadian-based oncology and endocrinology drug development company announced the closing of its previously announced public offering of 11.million shares. The offering is expected to generate net proceeds of about $12.2 million, with each unit consisting of one common share and 0.8 of a warrant to purchase one common share, at a purchase price of $1.20 per unit. Each warrant is exercisable for a period of five years at an exercise price of $1.25 per share. Canaccord Genuity Inc. acted as the sole book-running manager, and Maxim Group LLC, H. C. Wainwright & Co., LLC and MLV & Co LLC acted as co-managers for the Offering.

Aeterna Zentaris said it would use the net proceeds to in develop new treatments in oncology and endocrinology.

Find out what could be the best investor’s move when it comes to AEZS by getting the complete report here, or by cutting and pasting the following link in your Web browser. 

ABOUT US: issues momentum alerts on stocks that can provide gains to day traders. provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here:

Disclosure is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.